Vertex Announces Retirement of Peter Mueller, Ph.D.
July 10 2014 - 8:00AM
Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced that Peter Mueller, Ph.D., Executive Vice President of
Global Research and Development and Chief Scientific Officer, will
retire after more than 10 years with the company. Dr. Mueller’s
retirement will be effective October 31, 2014, following a planned
transition period. Dr. Mueller joined Vertex in 2003 as Chief
Scientific Officer and Senior Vice President, Drug Discovery and
Innovation.
“Peter is a visionary who embodied Vertex’s fearless pursuit of
transformational medicines,” said Jeffrey Leiden, M.D., Ph.D.,
Chairman, President and Chief Executive Officer of Vertex. “I thank
Peter for his leadership, innovation and dedication to Vertex over
the past decade.”
Jeffrey A. Chodakewitz, M.D., Vertex’s Senior Vice President of
Global Medicines Development and Medical Affairs and Chief Medical
Officer, will continue to oversee all global clinical development
programs and other related functions and will now assume additional
responsibility for Regulatory Affairs and Global Patient Safety.
Vertex expects to appoint a Head of Global Research to oversee the
company’s drug discovery efforts following Dr. Mueller’s
retirement.
About Vertex
Vertex is a global biotechnology company that aims to discover,
develop and commercialize innovative medicines so people with
serious diseases can lead better lives. In addition to our clinical
development programs focused on cystic fibrosis, Vertex has more
than a dozen ongoing research programs aimed at other serious and
life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research
and development sites and commercial offices in the United States,
Europe, Canada and Australia. For four years in a row, Science
magazine has named Vertex one of its Top Employers in the life
sciences. For additional information and the latest updates from
the company, please visit www.vrtx.com.
Vertex's press releases are available at www.vrtx.com.
Special Note Regarding Forward Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995,
including, without limitation, the statements in the third
paragraph of this press release. While Vertex believes the
forward-looking statements contained in this press release are
accurate, there are a number of factors that could cause actual
events or results to differ materially from those indicated by such
forward-looking statements. Those risks and uncertainties include,
among other things, the risks listed under Risk Factors in Vertex's
annual report and quarterly reports filed with the Securities and
Exchange Commission and available through the company's website
at www.vrtx.com. Vertex disclaims any obligation to update the
information contained in this press release as new information
becomes available.
(VRTX-GEN)
Vertex Pharmaceuticals IncorporatedMediaMegan Pace
617-341-6992mediainfo@vrtx.comorInvestorsMichael Partridge,
617-341-6108orKelly Lewis, 617-961-7530
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024